By analyzing the relationship between the expression of ERCC1 protein in tumor resection samples of NSCLC patients at stage I∼IIIA and postoperative survival, and taking the postoperative survival time as the final index to study the difference of curative effect in the chemotherapy group, Wang et al. [39] discussed the significance of ERCC1 expression in judging the prognosis of different patients and the existence of cisplatin resistance. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.